Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK] NYSE:ACT
[IN] FIN PHA HEA MTC
[SU]
-- WITH PHOTO -- TO BUSINESS, AND FOREIGN EDITORS:
Actavis Completes Divestiture of Commercial Operations in Seven
Western European Countries to Aurobindo Pharma Limited
DUBLIN, April 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today
announced that it has successfully completed the divestiture of its
generics commercial operations in seven markets in Western Europe to
Aurobindo Pharma Limited (BSE: 524804). The agreement to divest the
commercial operations was announced in January 2014.
Aurobindo acquired Actavis' pharmaceutical commercial infrastructure
in France, Italy, Spain, Portugal, Belgium, Germany and the
Netherlands, including products, marketing authorizations and dossier
license rights. The two companies also entered into a long-term
strategic supply arrangement.
About Actavis Actavis plc (NYSE: ACT) is a global, integrated
specialty pharmaceutical company focused on developing, manufacturing
and distributing generic, brand and biosimilar products. Actavis has
global headquarters in Dublin, Ireland and U.S. administrative
headquarters in Parsippany, New Jersey, USA.
Actavis develops and manufactures generic, brand, branded generic,
legacy brands and Over-the-Counter (OTC) pharmaceutical products and
has commercial operations in approximately 60 countries. The
Company's North American branded pharmaceuticals business is focused
principally in the Women's Health, Urology, Gastroenterology and
Dermatology therapeutic categories with a strong pipeline of products
in various stages of development. Actavis also has a portfolio of
five biosimilar products in development in Women's Health and
Oncology. Actavis Global Operations has more than 30 manufacturing
and distribution facilities around the world, and includes Anda, Inc.,
a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web
site at http://www.actavis.com.
About Aurobindo Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures generic
pharmaceuticals and active pharmaceutical ingredients. The company's
manufacturing facilities are approved by several leading regulatory
agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa,
ANVISA Brazil. The company's robust product portfolio is spread over 6
major therapeutic/product areas encompassing Antibiotics,
Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics,
supported by an outstanding R&D set-up. The Company is marketing these
products globally, in over 125 countries.
Aurobindo Europe represents a significant segment within the Group's
global presence. Aurobindo is committed to grow its operations in
Europe considering the importance of the generic market. Since
launching its European commercial operations in 2006 with the
acquisition of Milpharm in the UK and Pharmacin in the Netherlands in
2007, Aurobindo has further expanded its footprint in continental
Europe by commencing operations in several territories including (but
not limited to) Italy, Spain, Portugal, Romania, Malta and Germany.
Aurobindo's state of the art EU release lab and captive warehouse in
Malta serves as a logistics centre for its European operations.
Actavis Forward-Looking Statement Any statements contained in this
press release that refer to future events or other non-historical
facts are forward-looking statements that reflect Actavis' current
perspective of existing trends and information as of the date of this
release. Except as expressly required by law, Actavis disclaims any
intent or obligation to update these forward-looking statements.
Actual results may differ materially from Actavis' current
expectations depending upon a number of factors affecting Actavis'
business. These factors include, among others, the impact of
competitive products and pricing; market acceptance of and continued
demand for Actavis' products; difficulties or delays in manufacturing;
the difficulty of predicting the timing or outcome of regulatory
agency approvals or actions, if any; and other risks and uncertainties
detailed in Actavis' periodic public filings with the Securities and
Exchange Commission, including but not limited to Actavis plc's Annual
Report on Form 10-K for the year ended December 31, 2013. Except as
expressly required by law, Actavis disclaims any intent or obligation
to update these forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
CONTACTS:
Investors: Lisa DeFrancesco (862) 261-7152
Media: Charlie Mayr (862) 261-8030
David Belian (862) 261-8141
SOURCE Actavis plc
-0- 04/01/2014
/Photo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
(NYSE:ACT) /
CO: Actavis plc
ST: Europe Ireland
IN: FIN PHA HEA MTC
PRN
-- NY94734 --
0000 04/01/2014 12:00:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
